CD200, Avi-Tag, His-Tag, Biotin-Labeled Recombinant

Only %1 left
Catalog #
102031
As low as $295 *

Cat # Size Price*

Qty
*US Pricing only. For international pricing, please contact your local distributor.
Purchase
Description

Recombinant human CD200 (cluster of differentiation 200), encompassing amino acids 31-232. This construct contains a C-terminal Avi-Tag™, followed by a His-tag (6xHis). This protein was affinity purified.

Synonyms
OX-2 membrane glycoprotein, MOX1, MOX2, My033
Product Info
Storage and Usage
Citations
Species
Human
Construct
CD200 (31-232-Avi-His)-(Biotin)
Host Species/Expression System
HEK293
Purity

≥90%

Format

Aqueous buffer solution.

Formulation

8 mM phosphate, pH 7.4, 110 mM NaCl, 2.2 mM KCl, and 20% glycerol

MW
26 kDa + glycans
Amino Acids
31-232
Glycosylation
This protein runs at a higher MW by SDS-PAGE due to glycosylation.
Genbank #
NM_005944.7
UniProt #
P41217
Tag(s)
C-terminal Avi-Tag™, His-Tag
Label

This protein is enzymatically biotinylated using Avi-Tag™ technology. Biotinylation is confirmed to be ≥90%.

For more information on enzymatic biotinylation, please see our Tech Note.

Background

CD200 (cluster of differentiation 200), also known as OX-2, is type 1 membrane glycoprotein of the immunoglobulin supergene family. It is structurally related to the B7 family of costimulatory receptors. It is found in cells of the myeloid and lymphoid lineage, such as activated T and B cells, neurons, endothelial cells, and cancer cells. Its expression depends on IFN-γ (interferon gamma) and TNF-α (tumor necrosis factor alpha), and it is regulated by C/EBP-β. When bound to CD200R (CD200 receptor) it contributes to the formation of an immunosuppressive TEM (tumor microenvironment), via a Dok1 (docking protein 1), Dok2 and RasGAP dependent mechanism, leading to T cell responses inhibition, NK cell cytotoxicity decrease, potentiation of Treg cell expansion and decrease of other immune responses to cancer cells. CD200 can be found in a soluble form at high levels in the serum of cancer patients, linking to a poor prognosis. A splice variant missing exon 2, CD200tr, can also be formed, and it may act as a competitive inhibitor for full length CD200. In addition to cancer, CD200 is linked to auto-immune disorders, inflammation, infection, and graft survival. Samalizumab, an anti-CD200 monoclonal antibody, has resulted in positive outcomes when used in patients suffering from CLL (chronic lymphocytic leukemia) and MM (multiple myeloma).